Skip to content
POM-V Prescription Required Companion Animal

Canixin DHPPi Lyophilisate and Solvent for Suspension for Injection for Dogs

Active ingredients: Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus

Form

Injection

Species

Dogs

Manufacturer

Virbac

VMD MA No.

05653/4201

What it's used for

In the duration of immunity studies one year after the basic vaccination scheme there was no significant difference between vaccinated and control dogs in...

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Canine adenovirus + Canine d...

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Canixin DHPPi Lyophilisate and Solvent for Suspension for Injection for Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

In the duration of immunity studies one year after the basic vaccination scheme there
was no significant difference between vaccinated and control dogs in viral excretion for
CPiV or CAV-2.
After the annual booster, the duration of immunity lasts for 3 years for CDV, CAV-1, CAV-
2 and CPV and 1 year for CPiV.
For CAV-2, the duration of immunity after the annual booster was not established by
challenge, and is based on the presence of CAV-2 antibodies 3 years after the booster
vaccination.
When an early vaccination is recommended in susceptible puppies (see section 3.4), an
additional injection from 6 weeks of age can be performed; followed 2 weeks later (from 8
weeks of age) by the usual vaccination scheme (2 injections performed at a 3-4 weeks
interval).
Re-vaccinations:
One booster injection of a single dose should be given 1 year after the primary
vaccination course.
Subsequent vaccinations are carried out at intervals of up to three years.
Annual revaccination is required for the CPiV component.
When active immunisation against Leptospira
vaccine can be used instead of the solvent. After reconstitution of one dose of the
product with one dose of Virbac’s Leptospira vaccine, shake gently (the reconstituted
product is slightly pinkish beige) and administer immediately one dose of 1 ml
subcutaneously according to the same vaccination schedule as above (annual
revaccination required for the Leptospira component). Refer to the Virbac's Leptospira's
vaccine product information regarding vaccination scheme against Leptospira.
When active immunisation against rabies is also required, and if Virbac’s rabies vaccine
is available, 1 dose of Virbac’s rabies vaccine can be used instead of the solvent. Refer
to the Virbac’s rabies vaccine product information regarding vaccination scheme against
rabies.
AN: 02662/2024 & 02664/2024
None.
Dogs:
Common
(1 to 10 animals / 100 animals
treated):
Injection site swelling
1,2,3
, Injection site oedema
2,3,4
Lethargy
Rare
(1 to 10 animals / 10,000 animals
treated):
Injection site pain
2,3
, Injection site pruritus
2,3
Hyperthermia
, Anorexia
Digestive tract disorders
(e.g. Diarrhoea
,
Vomiting
)
Very rare
(<1 animal / 10 000 animals treated,
including isolated reports):
Hypersensitivity reaction (e.g. Anaphylaxis,
Allergic skin reaction such as Allergic oedema,
Urticarial erythema, Allergic pruritus)
1
(≤ 4 cm). In puppies of 6 weeks of age, swelling (≤ 2cm) sometimes associated with
pain and sometimes followed by nodules (≤
very commonly observed (refer to symptoms of overdose section).
Transient
Resolves spontaneously within 1 to 2 weeks.
Slight diffuse
Appropriate symptomatic treatment should be administered without delay.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Vaccinate healthy animals only.
In susceptible puppies suspected to present low levels of maternal derived antibodies
(i.e. born from non-vaccinated mothers, from large litters, poor feeders,...), an earlier
immunisation may be recommended by the veterinarian (i.e. in case of early puppy
socialisation, high risk environment,...) and the vaccination scheme should be adapted
accordingly (see section 3.9).
The presence of maternally derived antibodies (puppies from vaccinated females) may in
some cases interfere with the vaccination. Therefore the vaccination scheme should be
adapted accordingly (see section 3.9).
AN: 02662/2024 & 02664/2024

Special precautions for safe use in the target species:
After vaccination, the live viral vaccinal strains (CAV-2, CPV) can be spread to
unvaccinated animals without any pathological effect for these in-contact animals.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed
and administered with Virbac’s Leptospira vaccine containing the strains Leptospira
interrogans (serogroup Canicola serovar Canicola and serogroup Icterohaemorrhagiae
serovar Icterohaemorrhagiae) or Virbac’s rabies vaccine, if available.
No information is available on the safety and efficacy of this vaccine when used with any
other veterinary medicinal product except the products mentioned above. A decision to
use this vaccine before or after any other veterinary medicinal product therefore needs to
be made on a case-by-case basis.
Store and transport refrigerated (2 C – 8 C).
Protect from light.
AN: 02662/2024 & 02664/2024
Do not freeze.
Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.